Inhibikase Therapeutics Files 8-K on Financials
Ticker: IKT · Form: 8-K · Filed: Mar 27, 2025 · CIK: 1750149
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
Related Tickers: IKT
TL;DR
IKT filed an 8-K on 3/27/25 detailing financial condition and results of operations.
AI Summary
Inhibikase Therapeutics, Inc. filed an 8-K on March 27, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Atlanta, Georgia.
Why It Matters
This filing provides crucial updates on Inhibikase Therapeutics' financial health and operational status, which are important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing providing standard financial and operational information without any immediate material events or changes.
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Registrant
- March 27, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Atlanta, Georgia (location) — Principal Executive Offices
- 001-39676 (identifier) — SEC File Number
FAQ
What specific financial information is being reported in this 8-K?
The 8-K indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was made on March 27, 2025.
What is the principal business address of Inhibikase Therapeutics, Inc.?
The principal executive offices are located at 3350 Riverwood Parkway SE, Suite 1900, Atlanta, Georgia 30339.
What is the SIC code for Inhibikase Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).
Under which section of the Securities Exchange Act of 1934 is this report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 27, 2025 regarding Inhibikase Therapeutics, Inc. (IKT).